<DOC>
	<DOCNO>NCT00170729</DOCNO>
	<brief_summary>The primary objective demonstrate two day treatment 0.5 % prednisolone acetate eye-drops cataract surgery superior vehicle reduce flare anterior chamber operate eye .</brief_summary>
	<brief_title>A Study Compare Ocular Safety Tolerability Eye Drops Containing Prednisolone Acetate Patients With Intraocular Inflammation After Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Capsule Opacification</mesh_term>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Patient give write informed consent . Patient &gt; 40 year age . Patient undergone cataract surgery accord standard surgical procedure ( see Appendix 2 Protocol ) . Patient show flare anterior chamber ≥ 20 photons/msec Day 1 compare preoperative value measure screen Patient give write informed consent . Ophthalmologic condition Operation perform accord standard procedure . Any eye condition urgently require treatment NSAIDs corticosteroid . History intraocular surgery operate eye . Any laser therapy cryotherapy operate eye 90 day precede surgery . Any previous episode uveitis operate eye . Clinically significant trichiasis clinically relevant concurrent inflammatory/ infective eye disorder ( e.g . conjunctivitis , episcleritis ) except mild form seborrheic blepharitis . Severe dry eye syndrome . Glaucoma . Any clinically significant disorder operate eye . Contact lens wearer treatment period . Systemic condition Hypersensitivity ingredients trial medication . Diabetes mellitus ( even currently control ) . Severe systemic dysfunction ( cardiac , pulmonary , hepatic , renal endocrine ) . Rheumatoid arthritis . Subjects history malignancy organ system , treat untreated , within past five year , whether evidence local recurrence metastasis exist , exclude , exception localize basal cell carcinoma skin . Prohibited concomitant medication Treatment eye ( operate ) local antiinflammatory drug 14 day precede surgery trial . Systemic use corticosteroid 4 week precede surgery trial . Inhaled corticosteroid allow stable 4 week precede trial trial . Topical corticosteroid treat dermatological disease allow , . Chronic systemic use NSAIDs 4 week prior trial trial , occasional use ( ≤ 2 time per week ) NSAIDs OTC painkiller treat minor condition acceptable . Low dose aspirin cardiovascular prophylaxis allow . Other prohibited condition Pregnant lactate woman childbearing potential unless adequate birth control method use throughout study . Mentally handicap subject . Alcohol/drug abuse . Concomitant recent use investigational agent within 3 month prior study start . Patient 's repeated participation trial . Any medical laboratory condition , Investigator 's opinion , would preclude participant adhere protocol complete trial per protocol . participation another clinical study within 4 week prior enrolment ; hematological disease aplastic anemia , panmyelopathy , hemolytic icterus ; severe dysfunction liver ; medical laboratory condition , Investigator 's opinion , would preclude participant adhere protocol complete trial per protocol ; subject history malignancy organ system , treat untreated , within past five year , whether evidence local recurrence metastasis exist , exclude , exception localize basal cell carcinoma skin .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Prednisolone acetate ,</keyword>
	<keyword>efficacy ,</keyword>
	<keyword>cataract ,</keyword>
	<keyword>eye drop ,</keyword>
	<keyword>tolerability ,</keyword>
	<keyword>inflammation</keyword>
</DOC>